To examine the involvement of KCTD9 in the anti-tumor effects of CSE, we delivered Lentivirus-encapsulated KCTD9 knockdown plasmid into LUAD cells, followed by CSE treatment. This evidence concerns the gene KCTD9 and neoplasm.